PriceTargets.com logo

Pasithea Therapeutics - KTTA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.00
  • Forecasted Upside: 490.55%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.51 As of 06/17/2026 01:28 PM ET
▼ -0.002 (-0.39%)

This chart shows the closing price for KTTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pasithea Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KTTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KTTA

Analyst Price Target is $3.00
▲ +490.55% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Pasithea Therapeutics in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 490.55% upside from the last price of $0.51.

This chart shows the closing price for KTTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in Pasithea Therapeutics. This rating changed within the last month from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
5/18/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/17/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/16/2026HC WainwrightReiterated RatingBuy ➝ Buy$3.00
6/1/2026Zacks ResearchUpgradeStrong Sell ➝ Hold
4/20/2026HC WainwrightReiterated RatingBuy ➝ Buy$3.00
4/2/2026Zacks ResearchDowngradeHold ➝ Strong Sell
3/27/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/15/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/9/2025Zacks ResearchUpgradeHold
12/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/8/2025HC WainwrightInitiated CoverageBuy$3.00
12/8/2025HC WainwrightInitiated CoverageBuy$3.00
12/1/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/17/2025Weiss RatingsReiterated RatingSell (E) ➝ Sell (E)
11/5/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/14/2025Weiss RatingsReiterated RatingSell (E) ➝ Sell (E)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
(Data available from 6/17/2021 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 7 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2026

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Pasithea Therapeutics logo
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Read More

Today's Range

Now: $0.51
Low: $0.49
High: $0.51

50 Day Range

MA: $0.71
Low: $0.51
High: $0.85

52 Week Range

Now: $0.51
Low: $0.28
High: $2.06

Volume

102,963 shs

Average Volume

362,487 shs

Market Capitalization

$12.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Pasithea Therapeutics?

The following Wall Street research analysts have issued research reports on Pasithea Therapeutics in the last year: HC Wainwright, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for KTTA.

What is the current price target for Pasithea Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Pasithea Therapeutics in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 488.2%. HC Wainwright has the highest price target set, predicting KTTA will reach $3.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $3.00 for Pasithea Therapeutics in the next year.
View the latest price targets for KTTA.

What is the current consensus analyst rating for Pasithea Therapeutics?

Pasithea Therapeutics currently has 1 sell rating, 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KTTA, but not buy more shares or sell existing shares.
View the latest ratings for KTTA.

What other companies compete with Pasithea Therapeutics?

Other companies that are similar to Pasithea Therapeutics include PDS Biotechnology, PMV Pharmaceuticals, Instil Bio, Prima BioMed and Xilio Therapeutics. Learn More about companies similar to Pasithea Therapeutics.

How do I contact Pasithea Therapeutics' investor relations team?

Pasithea Therapeutics' physical mailing address is 1111 Lincoln Road Suite 500, Miami Beach FL, 33139. The company's listed phone number is 702-514-4174 and its investor relations email address is [email protected]. The official website for Pasithea Therapeutics is www.pasithea.com. Learn More about contacing Pasithea Therapeutics investor relations.